COVID-19: Canada fails to develop vaccine with Cansino:

COVID-19: Canada fails to develop vaccine with Cansino:

-China is “foreclosure” just before the clinical trial-

“The Epoch Times” (January 30):

The Government of Canada was working on a vaccine development project with China Kansino,

“The Chinese customs carried out the seizure just before the clinical trial,” all failed.

Canadian Broadcasting Corporation (CBC)

It told you on January 27th.

Tianjin, China
Cansino Biological Company (Kanshino)

It was founded in 2009 by a Chinese scientist with experience studying in Canada.

Having a thick pipe at a Canadian research institute,
Using Canadian biotechnology,
Developed Ebola vaccine and Chinese virus vaccine.

NRC supplies with Cansino:

May 2020,

Vaccines will be supplied to Canada
The Government of Canada National Research Council (NRC)
A supply contract was signed with Kanshino.

Cansino Chinese Scientist:

Vaccine research conducted in China using Canadian biotechnology.

We managed to do a clinical trial in Canada.

It was a cooperation agreement on the development of the most advanced “mRNA” vaccine.

China Customs bans exports:

However, China Customs did not allow the “prototype” vaccine to be shipped to Canada.

Needless to say, “this is a breach of contract.”

This contract was not fulfilled and the basic technology was used without permission.

Clinical Trial Plan in Canada:

In May 2020, Canada planned to conduct a clinical trial of a vaccine developed by Cansino in Canada.

If the trial was successful, production was scheduled to begin at the Montreal plant in the summer.

NRC Report:

The Montreal plant was expected to produce 70,000 to 100,000 vaccines a month.

However, the Cansino vaccine was seized by Chinese customs authorities.

The Embassy of Canada in China protested against Chinese customs authorities but was rejected.

It is a “Chinese trick”.

Cansino Vaccine:

Later, an mRNA vaccine was developed in China.

However, it is reported that “the efficacy in clinical trials is around 50%”.

“Whether this vaccine uses Canadian basic technology” is unknown.

World view of Toshiyoshi Katsumata

How a failed deal with China to produce a made-in-Canada COVID-19 vaccine wasted months and millions

CanSino-McMaster deal may turn out to be ‘case study of what not to do in partnerships with China’: expert | CBC News

CanSino CEO says TB vaccine was promising | CBC.ca